Iovance Biotherapeutics (IOVA) drew fresh attention after reporting its fourth quarter and full year 2025 results, with revenue of US$86.77 million for the quarter and US$263.5 million for the year.

The recent earnings release and news flow have gone hand in hand with a sharp shift in sentiment. The 30 day share price return of 51.37% and 90 day share price return of 80.80% contrast with a 1 year total shareholder return decline of 4.46% as investors reassess both growth prospects and risk.

If strong moves in cancer therapy names have caught your eye, it could be a time to look at 28 healthcare AI stocks surfaced by the Simply Wall St screener as potential next ideas.

With Iovance posting strong revenue growth but still reporting a net loss of US$390.98 million in 2025, the key question is whether recent optimism leaves upside on the table or whether the market is already pricing in future growth.

Most Popular Narrative: 53.8% Undervalued

At a last close of $3.86 versus a narrative fair value of $8.35, the current price sits well below what this widely followed view suggests.

The fair value estimate was kept unchanged at US$8.35 per share, indicating no adjustment to the headline valuation output.

The discount rate moved slightly from 7.09% to 7.15%, reflecting a modest recalibration of the risk and return assumptions used in the model.

Want to see what justifies that higher fair value? The narrative highlights rapid revenue expansion, a swing to profitability and a rich earnings multiple. Curious which assumptions really carry the weight in that model?

Result: Fair Value of $8.35 (UNDERVALUED)

However, the story could look very different if Amtagvi demand slows or if further setbacks arise in securing approvals outside the U.S.

Another Angle on Valuation

The current narrative leans heavily on fair value estimates, yet the simple revenue multiple tells a tougher story. At a P/S of 6x versus a fair ratio of 4.2x, the share price sits higher than that reference point even though it is below the US Biotechs average of 12.5x and peer average of 8x. For you, that mix of discount and premium raises a basic question: is this more of a margin of safety or a reminder that expectations are already demanding?

Next Steps

If the mix of optimism and concern in this story feels familiar, it is a good moment to check the data yourself and decide where you stand. Start with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Iovance has you thinking about what else could be worth your attention, do not stop here. Broaden your watchlist with a few focused stock sets.

• Target income first by reviewing 13 dividend fortresses that could help you build a portfolio centered on reliable cash returns.
• Hunt for value by scanning screener containing 24 high quality undiscovered gems that the market may not be paying full attention to yet.
• Prioritise resilience by checking 76 resilient stocks with low risk scores that screen well on quality and risk metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.